Week In Review: Hengrui Out-Licenses Cancer Drug In $795 Million Deal
September 05, 2015 at 16:44 PM EDT
Jiangsu Hengrui Medicine out-licensed global rights (ex-China) for its clinical-stage anti-PD-1 monoclonal antibody to Incyte in a deal potentially worth $795 million.
